Pfizer Inc.

PFE

BCBA · XBUE · Argentina

Financial Research and Analysis

Pfizer's Buenos Aires depositary certificate

The PFE instrument in Buenos Aires is identified in the supplied information as an Argentine CEDEAR representing 0.25 underlying Pfizer share. A reference quote on 27 October 2026 was ARS 12,320. One source recorded a daily decline of 1.04%, while another showed a 1.44% decline at a different observation time. These should be treated as separate snapshots rather than synchronized observations.

Local price, liquidity and volatility

Previous close was ARS 12,450, with an intraday range of ARS 12,320 to ARS 12,470 and displayed volume of 23,346 units in the first snapshot. The 52-week range was ARS 8,800 to ARS 12,690. Comparisons with US Pfizer shares must account for the quarter-share representation, exchange rates, liquidity and fees. A price difference alone does not establish a risk-free arbitrage opportunity.

Distributions and conflicting provider metrics

One provider showed an indicated forward yield of approximately 5.23%, while another reported 5.31%. The supplied platforms also differ on market capitalization and valuation ratios, so the metrics should not be combined into a single consistent valuation without verifying their methodologies. An ex-dividend date of 6 November 2026 was indicated. Investors should confirm depositary arrangements and distribution entitlements.

Buenos Aires listing questions

Is PFE.BA identical to one US Pfizer share? The supplied instrument description identifies a depositary certificate representing one quarter of an underlying share. What is its currency? Argentine pesos. Does ARS 12,320 mean USD 12,320? No. Can the Frankfurt quote replace its unavailable market data? No, because venue, currency and security structure differ.

Pfizer and its core businesses

Founded in 1849, Pfizer develops, manufactures and markets medicines and vaccines worldwide. Its portfolio includes Eliquis, Prevnar, Paxlovid and specialized oncology treatments. Research productivity, regulatory approvals, competition and product exclusivity are important drivers of business performance. Patent expiration, clinical trial costs and changes in medicine pricing are material risks.

Consolidated financial performance

The supplied figures show Pfizer revenue of USD 62.58 billion in 2025 versus USD 63.63 billion in 2024, a decline of 1.65%. Reported annual earnings were USD 7.77 billion. These represent the consolidated US issuer rather than separate results for Frankfurt trading or the Argentine depositary instrument. The financial condition of the company and the trading price of a local instrument are different concepts.

Product portfolio and growth prospects

Vaccines, oncology and specialty medicines remain important to Pfizer's business. The October 2026 materials provided refer to clinical developments involving ELREXFIO and expanded regulatory approvals for certain oncology treatments. Clinical progress alone does not establish commercial success. Regulatory authorization, competition, patient access, pricing and execution remain important variables.

Dividend sustainability

Evaluating Pfizer's dividends requires consideration of formal declarations, cash generation, financial obligations and investment in drug development. A historical or indicated dividend yield is not a guarantee of future payments. Investors in international instruments also need to assess withholding, custody fees, currency conversion and the instrument's specific economic rights.

Investment valuation and risks

Pfizer faces pharmaceutical competition, patent expiration, health-policy changes, litigation, clinical-development uncertainty and exchange-rate exposure. Price-to-earnings ratios must be assessed alongside the reporting period, earnings quality and security structure. A historical price rise or decline does not by itself establish investment value. This material is educational and is not investment advice.

Comparing earnings across reporting periods

Financial analysis starts with the reporting period associated with each figure. Annual revenue should not be compared directly with one quarter without adjusting for the period covered. Earnings per share may include nonrecurring effects, and accounting profits do not always match cash generated by operations. Liquidity, debt repayment and investment capacity depend on cash resources as well as reported earnings. Multi-year comparisons help distinguish changes in product demand from temporary accounting or restructuring effects.

Product exclusivity and the development pipeline

Intellectual-property rights are central to pharmaceutical economics. When product exclusivity expires, competing therapies may reduce revenue and pricing power. Investors therefore need to monitor expected exclusivity losses as well as new medicine approvals and launch execution. Experimental therapies should not be treated as certain future revenue streams. Clinical success, regulatory authorization, pricing access and commercial adoption are separate hurdles, each of which can materially influence an investment thesis.

Interest rates, financing and debt

Interest rates influence borrowing costs and the present value attributed to future cash flows. Higher financing expenses can constrain investment in research or acquisition opportunities, although operational performance is often more important than rate movements alone. Debt maturities, available liquidity and future commitments should be examined alongside cash generation. Lower interest rates do not automatically translate into better earnings if product sales, competitive dynamics or execution deteriorate.

Interpreting valuation multiples

A trailing earnings multiple relates price to realized earnings, while a forward multiple depends on projections that can change. A high P/E may result from temporarily depressed profits rather than an unusually high price. International depositary instruments introduce another complication because their quotation units, underlying-share ratios, currencies and provider methodologies can differ. A multiple should not be compared across instruments without confirming exactly which earnings and security units its calculation uses.

Dividend payments and foreign currency

Distribution analysis requires identifying the payment currency, entitlement per underlying share and the number of shares represented by each local instrument. Exchange conversion, custody charges, withholding arrangements and broker fees can all affect net investor receipts. A yield reported for a US share is not necessarily identical to the cash outcome for an international depositary certificate. Falling market prices can also raise an indicated yield without increasing the actual dividend payment.

Source methodology and data limitations

Quoted prices and market statistics in these profiles are dated reference observations rather than real-time market feeds. Different providers may report different percentage changes or capitalization measures because they capture separate moments or apply different instrument definitions. Conflicting values should be disclosed rather than forced into an unsupported combined estimate. Material corporate facts should be cross-checked against issuer filings and exchange documentation before being relied upon.

Questions investors should answer

Before investing, determine the precise legal security held, its quotation and settlement currencies, trading hours, liquidity and bid-ask spread. Confirm any depositary ratio, distribution entitlement, custody costs and conversion charges. Understand how the instrument tracks the underlying issuer and why its return may differ after currency movements. Finally, evaluate the issuer's product portfolio, cash generation, debt obligations, development pipeline and business risks separately from the local trading mechanics.

Buenos Aires exchange and BYMA

BYMA provides a major securities-market infrastructure in Argentina, supporting trading in equities, debt securities, depositary instruments and other financial products under applicable rules. Argentine Depositary Receipts, known as CEDEARs, provide local-market exposure to assets issued abroad. Investors must distinguish the foreign issuing company from the locally traded certificate. Pfizer is a US pharmaceutical issuer, while PFE.BA is an Argentine market instrument linked to that issuer. The company does not generate separate consolidated operating results merely because its exposure is available through an Argentine depositary instrument.

How a CEDEAR represents foreign shares

BYMA describes CEDEARs as locally issued instruments backed by foreign underlying assets held through depositary arrangements. Each security has a defined conversion ratio. The supplied Pfizer instrument description indicates that one certificate represents one quarter of an underlying Pfizer share, implying four certificates per underlying share on a representation basis, subject to the applicable product terms. That ratio matters when evaluating price comparisons, distributions and exposure. It does not imply identical liquidity, trading costs, currency denomination or execution conditions between Buenos Aires and New York.

Custody, intermediaries and settlement choices

BYMA explains that CEDEARs are traded through authorized local intermediaries and held through Caja de Valores. Settlement and the timing of security credits depend on the chosen transaction arrangements. Investors should confirm the applicable settlement option, trading permissions and security entitlements with their intermediary before placing an order. Conversion from a certificate into its represented foreign asset can also depend on the security's product documentation and related costs. Depositary charges, brokerage fees, taxes and currency conversion can reduce the final return received by an investor.

Argentine peso exposure and exchange rates

PFE.BA is quoted in Argentine pesos, whereas Pfizer's primary US share is denominated in dollars. Differences in the depositary ratio, foreign exchange rates, local liquidity and execution costs affect how the quotations compare. Simply multiplying a US share price by one exchange rate without applying the certificate ratio and product terms can produce a misleading result. A peso-denominated certificate may rise even when the underlying foreign share changes little if the local currency weakens. A positive ARS return is therefore not necessarily the same as a positive USD return.

Dividends and CEDEAR-specific risks

BYMA explains that CEDEARs can provide exposure to distributions associated with the underlying foreign assets, subject to each product's terms. Payments received may be affected by the conversion ratio, custody arrangements, withholding and other charges. Trading activity and bid-ask spreads can differ significantly from the foreign share's main market. Investors should read official depositary documents and payment announcements rather than treating an indicated yield as guaranteed. GoFinsa does not represent the historical certificate quotation as a live executable price or guarantee future distributions.

Educational research and dated reference snapshots, not investment advice or live quotes.